Thursday, December 26, 2024 12/26/2024

A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)

Award Number: R01FD006371
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

PROJECT SUMMARY/ABSTRACT Duchenne muscular dystrophy (DMD) is a rare and fatal disease affecting approximately 1 in every 3,500 live male births across all races and cultures with no cure. DMD results in loss of ambulation, respiratory failure, cardiomyopathy (CM), and premature death. CM is now the leading cause of death in DMD. Limited ambulation in DMD patients often masks typical symptoms of heart failure, allowing unchecked CM disease progression. Without aggressive screening in DMD, the first manifestation of CM can be irreversible heart failure or sudden cardiac death. Our group and others have shown activation of the thromboxane prostanoid receptor (TPr) located on platelets, immune cells, smooth muscle and cardiomyocytes contributes to deleterious effects in the heart. Further, TPr blockade with the potent and selective TPr antagonist, ifetroban, prevents cardiac fibrosis, improves cardiac function and mortality in multiple animal models of DMD CM. Isoprostanes (IP) activate the TPr and are elevated in DMD. Not only are they the most reliable marker for assessing oxidative stress, IP are mediators of vascular dysfunction. They perpetuate the inflammatory response to oxidant injury, which may play a key role in DMD CM pathogenesis. Our overall goal is to determine the safety and efficacy of ifetroban to support its approval for the treatment of DMD CM, a rare condition where no current therapy exists thereby directly serving the Orphan Products Development’s mission. The proposed clinical study aims to determine the safety, pharmacokinetics and efficacy of oral ifetroban in patients with DMD CM. In addition to quantitative cardiac and respiratory outcomes, the measurable effect of oral ifetroban on muscle strength, daily activity and quality-of-life will be investigated in DMD patients. This randomized, placebo-controlled, multicenter phase 2 trial is designed to test the central hypothesis that TPr signaling promotes cardiac inflammation and drives IP overproduction contributing to DMD CM, thereby perpetuating the inflammatory response which leads to cardiac fibrosis and vascular dysfunction. Aim 1 will determine the safety and efficacy of ifetroban, an oral TPr antagonist, as treatment for DMD CM. A network of pediatric cardiologists with DMD and cardiac imaging expertise at the largest DMD centers in the country will expedite enrollment for this rare disease. The same imaging equipment and standardized cardiac imaging protocol will be used to compare cardiac imaging data across centers. Aim 2 will determine the effect of TPr blockade on protein expression and CMR structures. Specimens and imaging will be used to determine the effects of TPr blockade on skeletal muscle and CM disease progression. Successful completion of this phase 2 trial will help support the approval of ifetroban for treatment of DMD CM. Study outcomes will provide the necessary information for design of the pivotal phase 3 study to have the greatest impact on reducing death and disability in patients with DMD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2019	CUMBERLAND PHARMACEUTICALS, INC.	1600 W END AVE STE 1300	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	000	1	11/26/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2019	CUMBERLAND PHARMACEUTICALS, INC.	SUITE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	000	1	8/30/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	000	1	8/5/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $97,112 )
2020	2020	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	001	1	9/16/2020	SUPPLEMENT FOR EXPANSION	$97,112
2020	2019	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	000	1	11/8/2019	NEW	$0
														Subtotal = $97,112

Issue Date FY: 2019 ( Subtotal = $1,069,742 )
2019	2019	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	002	1	9/28/2019	NEW	$769,742
2019	2019	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	001	1	9/18/2019	NEW	$0
2019	2019	CUMBERLAND PHARMACEUTICALS INC.	2525 WEST END AVE STE 950	NASHVILLE	TN	37203	DAVIDSON	USA	Food and Drug Administration Research	000	1	9/12/2019	NEW	$300,000
														Subtotal = $1,069,742

Grand Total All Awards = $1,166,854

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)

Award Number: R01FD006371

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer